Phase 1 N=50 A Pilot Study of Genetically Engineered NY-ESO-1 Specific NY-ESO-1ᶜ²⁵⁹T in HLA-A2+ Patients With Synovial Sarcoma
Neoplasms
Primary: Objective Response Rate (ORR) — 50; 30.8; 20; 26.7 Percentage of Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Early Phase 1 N=39 A Study of Pembrolizumab on the Tumoral Immunoprofile of Gynecologic Cancers
Gynecologic Neoplasms · Epithelial Ovarian Cancer · Uterine Endometrial Cancer
Primary: Change in Tumor Immune Infiltrates as Measured by PD-L1 Modified H-Score — 13.2 score on a scale
N/A N=9 Biosynthesis of PGD2 in Vivo
Hyperlipidemia
Primary: Percentage Change of Area Under Curve for the Urinary Prostaglandins Concentration Versus Time Curve (AUC) in Response to Aspirin or Placebo — 95; 43 Percentage change…
Phase 2 N=97 Phase II Investigation of Antimycobacterial Therapy on Progressive, Pulmonary Sarcoidosis
Sarcoidosis; Antimycobacterial Therapy
Primary: Change in Percent Predicted Absolute Forced Vital Capacity (FVC) in Participants With Pulmonary Sarcoidosis, Comparing Baseline With Performance After Completion of 16…
N/A N=1,799 EHR-based Decision Support for Pediatric Acute Abdominal Pain in Emergency Care
Appendicitis
Primary: Pre to Post Ratio of Image Use — 1.13; 1.07; 1.03; 1.01 ratio of pre-post use
Phase 2 N=96 Trilaciclib (G1T28), a CDK 4/6 Inhibitor, in Combination With Etoposide and Carboplatin in Extensive Stage Small Cell Lung Cancer (SCLC)
Small Cell Lung Cancer
Primary: Number of Participants With Dose Limiting Toxicities by Cohort in Cycle 1, Part 1 — 2; 1; 1; 0 Participants
N/A N=1,489 This Study Uses the SITS Registry to Find Out When Patients With a Heart Rhythm Disorder (Atrial Fibrillation) Start Treatment With Dabigatran After They Had a Stroke
Atrial Fibrillation
Primary: Percentage of Patients With Non-Valvular Atrial Fibrillation (NVAF) According to the Timing of Dabigatran Initiation After the First Ever Ischaemic Stroke (the Index…
N/A N=72 Daily Disposable Dispensing Clinical Trial of Test Lens Against Stenfilcon A Lens
Myopia
Primary: Subjective Ratings on Comfort — 9.7; 9.6 units on a scale
N/A N=48 Modeling Mood Course to Detect Markers of Effective Adaptive Interventions
Bipolar Disorder
Primary: Proportion of Participants Who Report They Are More Likely to Use a Smart-phone App Over an Activity Tracker to Monitor Their Symptoms — 0.404 proportion of participants
Phase 1 N=66 A Study of Necitumumab and Abemaciclib in Participants With Non-Small Cell Lung Cancer (NSCLC)
Carcinoma, Non-Small-Cell Lung · Neoplasm Metastasis
Primary: Part A: Number of Participants With Abemaciclib Dose Limiting Toxicities (DLTs) — 0; 1; 3 Participants
Phase 2 N=27 A Study of IL-7 to Restore Absolute Lymphocyte Counts in Sepsis Patients
Severe Sepsis With Septic Shock
Primary: Immune Reconstitution of Lymphocytopenic Sepsis Patients — 8; 7; 8 Participants
Phase 2 N=135 A Study of Tiragolumab in Combination With Atezolizumab in Chemotherapy-Naïve Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Non-small Cell Lung Cancer
Primary: Objective Response Rate (ORR) — 16.2; 31.3 percentage of participants — p=0.0310
Phase 2 N=43 RAD001 and Temozolomide in Patients With Advanced Pancreatic Neuroendocrine Tumors
Pancreatic Neuroendocrine Tumor
Primary: Response Rate — 16 Participants
N/A N=1,485 Career Enhancement Training Study (USAF)
Suicidal Ideation
Primary: Mean Computerized Adaptive Testing for Suicide Severity — 10.76; 12.12 units on a scale — p=.062
Phase 2 N=131 Fixed Versus Weight-Based Enoxaparin Dosing in Thoracic Surgery Patients
Venous Thromboembolism · Deep Venous Thrombosis · Surgery
Primary: Number of Patients With in Range Initial Peak Xa Level — 27; 27 Participants